Medication Adherence and Antithrombotic Therapy Outcomes

Puntos clave

• The study aims to evaluate the efficacy and safety of rivaroxaban monotherapy versus combination therapy in atrial fibrillation patients with stable coronary artery disease.
• Utilized data from the AFIRE trial focusing on atrial fibrillation and coronary artery disease.
• Compared outcomes of rivaroxaban monotherapy to combination therapy (rivaroxaban plus single antiplatelet).
• Analyzed efficacy and safety metrics between the two treatment groups.
• Rivaroxaban monotherapy was shown to have noninferior efficacy compared to combination therapy.
• Monotherapy demonstrated superior safety in patients with stable coronary artery disease.

PICO estructurado

Resumen